M&T Bank Corp increased its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) by 90.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 51,108 shares of the company’s stock after acquiring an additional 24,236 shares during the quarter. M&T Bank Corp owned about 0.16% of 4D Molecular Therapeutics worth $356,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Deep Track Capital LP boosted its stake in 4D Molecular Therapeutics by 28.9% during the first quarter. Deep Track Capital LP now owns 2,448,200 shares of the company’s stock worth $37,017,000 after buying an additional 548,200 shares in the last quarter. State Street Corp boosted its stake in 4D Molecular Therapeutics by 18.2% during the first quarter. State Street Corp now owns 1,489,371 shares of the company’s stock worth $22,519,000 after buying an additional 229,711 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in 4D Molecular Therapeutics by 29.7% during the first quarter. JPMorgan Chase & Co. now owns 367,545 shares of the company’s stock worth $5,557,000 after buying an additional 84,158 shares in the last quarter. BlackRock Inc. boosted its stake in 4D Molecular Therapeutics by 2.0% during the first quarter. BlackRock Inc. now owns 2,130,226 shares of the company’s stock worth $32,208,000 after buying an additional 42,544 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in 4D Molecular Therapeutics by 125.3% during the first quarter. Goldman Sachs Group Inc. now owns 75,458 shares of the company’s stock worth $1,141,000 after buying an additional 41,963 shares in the last quarter. Institutional investors own 92.94% of the company’s stock.
4D Molecular Therapeutics Stock Performance
Shares of NASDAQ:FDMT opened at $13.49 on Tuesday. 4D Molecular Therapeutics, Inc. has a 52 week low of $5.32 and a 52 week high of $25.05. The company’s fifty day moving average is $8.38 and its 200-day moving average is $8.54. The company has a market capitalization of $436.97 million, a PE ratio of -4.05 and a beta of 1.46.
Analysts Set New Price Targets
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc, a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.
- Get a free copy of the StockNews.com research report on 4D Molecular Therapeutics (FDMT)
- Wayfair Still Has Its Fair Share of Issues
- Why did NIO take a $581.11 million loss last quarter?
- This Mid-Cap Tech Stock Embodies Diversified Growth
- Take Two Interactive Software Stock is Taking One Step Back
- Is It Time To Take A Ride With Joby Aviation’s EV Innovations?
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.